The medication was created by Axsome Therapeutics, a pharmaceutical company that develops treatments for central nervous system disorders.
“[Auvelity] represents the first new oral non-monoamine-based mechanism of action approved to treat major depressive disorder in over sixty years,” Maurizio Fava, MD, psychiatrist-in-chief, Massachusetts General Hospital, said in a Aug.19 news release from Axsome.
“Given the debilitating nature of depression, the efficacy of Auvelity observed at one week and sustained thereafter may have a significant impact on the current treatment paradigm for this condition,” Dr. Fava said.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
